Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, Strangfeld A, Gossec L, Carmona L, Mateus EF, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Pons-Estel GJ, Isnardi CA, Berbotto GA, Hsu TY, D'Silva KM, Patel NJ, Kearsley-Fleet L, Schäfer M, Ribeiro SLE, Al Emadi S, Tidblad L, Scirè CA, Raffeiner B, Thomas T, Flipo RM, Avouac J, Seror R, Bernardes M, Cunha MM, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, Souza VA, Mota LMHD, Gomides APM, Dieudé P, Nikiphorou E, Kronzer VL, Singh N, Ugarte-Gil MF, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Yazdany J, COVID-19 Global Rheumatology Alliance

Open source

DOI: 10.1136/annrheumdis-2021-220418
Published: 2021 Sep
Container: Annals of the rheumatic diseases
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/annrheumdis-2021-220418,
  title = {Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.},
  author = {Sparks JA and Wallace ZS and Seet AM and Gianfrancesco MA and Izadi Z and Hyrich KL and Strangfeld A and Gossec L and Carmona L and Mateus EF and Lawson-Tovey S and Trupin L and Rush S and Katz P and Schmajuk G and Jacobsohn L and Wise L and Gilbert EL and Duarte-García A and Valenzuela-Almada MO and Pons-Estel GJ and Isnardi CA and Berbotto GA and Hsu TY and D'Silva KM and Patel NJ and Kearsley-Fleet L and Schäfer M and Ribeiro SLE and Al Emadi S and Tidblad L and Scirè CA and Raffeiner B and Thomas T and Flipo RM and Avouac J and Seror R and Bernardes M and Cunha MM and Hasseli R and Schulze-Koops H and Müller-Ladner U and Specker C and Souza VA and Mota LMHD and Gomides APM and Dieudé P and Nikiphorou E and Kronzer VL and Singh N and Ugarte-Gil MF and Wallace B and Akpabio A and Thomas R and Bhana S and Costello W and Grainger R and Hausmann JS and Liew JW and Sirotich E and Sufka P and Robinson PC and Machado PM and Yazdany J and COVID-19 Global Rheumatology Alliance},
  year = {2021},
  journal = {Annals of the rheumatic diseases},
  doi = {10.1136/annrheumdis-2021-220418},
  url = {https://doi.org/10.1136/annrheumdis-2021-220418}
}

RIS

TY  - JOUR
TI  - Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
AU  - Sparks JA
AU  - Wallace ZS
AU  - Seet AM
AU  - Gianfrancesco MA
AU  - Izadi Z
AU  - Hyrich KL
AU  - Strangfeld A
AU  - Gossec L
AU  - Carmona L
AU  - Mateus EF
AU  - Lawson-Tovey S
AU  - Trupin L
AU  - Rush S
AU  - Katz P
AU  - Schmajuk G
AU  - Jacobsohn L
AU  - Wise L
AU  - Gilbert EL
AU  - Duarte-García A
AU  - Valenzuela-Almada MO
AU  - Pons-Estel GJ
AU  - Isnardi CA
AU  - Berbotto GA
AU  - Hsu TY
AU  - D'Silva KM
AU  - Patel NJ
AU  - Kearsley-Fleet L
AU  - Schäfer M
AU  - Ribeiro SLE
AU  - Al Emadi S
AU  - Tidblad L
AU  - Scirè CA
AU  - Raffeiner B
AU  - Thomas T
AU  - Flipo RM
AU  - Avouac J
AU  - Seror R
AU  - Bernardes M
AU  - Cunha MM
AU  - Hasseli R
AU  - Schulze-Koops H
AU  - Müller-Ladner U
AU  - Specker C
AU  - Souza VA
AU  - Mota LMHD
AU  - Gomides APM
AU  - Dieudé P
AU  - Nikiphorou E
AU  - Kronzer VL
AU  - Singh N
AU  - Ugarte-Gil MF
AU  - Wallace B
AU  - Akpabio A
AU  - Thomas R
AU  - Bhana S
AU  - Costello W
AU  - Grainger R
AU  - Hausmann JS
AU  - Liew JW
AU  - Sirotich E
AU  - Sufka P
AU  - Robinson PC
AU  - Machado PM
AU  - Yazdany J
AU  - COVID-19 Global Rheumatology Alliance
PY  - 2021
JO  - Annals of the rheumatic diseases
DO  - 10.1136/annrheumdis-2021-220418
UR  - https://doi.org/10.1136/annrheumdis-2021-220418
ER  -

APA

JA, S., ZS, W., AM, S., MA, G., Z, I., KL, H., A, S., L, G., L, C., EF, M., S, L., L, T., S, R., P, K., G, S., L, J., L, W., EL, G., A, D., MO, V., GJ, P., CA, I., GA, B., TY, H., KM, D., NJ, P., L, K., M, S., SLE, R., S, A. E., L, T., CA, S., B, R., T, T., RM, F., J, A., R, S., M, B., MM, C., R, H., H, S., U, M., C, S., VA, S., LMHD, M., APM, G., P, D., E, N., VL, K., N, S., MF, U., B, W., A, A., R, T., S, B., W, C., R, G., JS, H., JW, L., E, S., P, S., PC, R., PM, M., J, Y., & Alliance, C. G. R. (2021). Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.. Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2021-220418

Source records

pubmed · retrieved 2026-09-26T18:26:53.639Z